|
Published studies of ovarian suppression with gonadotropin-releasing hormone agonists |
|||||||||
| Reference |
Year |
Patients (n) |
Chemotherapy regimen |
Pregnancies (%) |
Births (%) |
Menses 1 year after therapy (%) |
Menses at the end of follow-up (%) |
Study type |
Outcome |
|
|
|||||||||
| Fox and colleagues [27] |
2003 |
24 |
AC, AC-T, FAC, AT-CMF |
21 |
8 |
96 |
75 |
Prospective, single-arm |
Ovarian function preservation |
| Del Mastro and colleagues [28] |
2006 |
29 |
100% FEC |
- |
- |
94 |
92 |
Prospective, single-arm |
Ovarian function preservation |
| Recchia and colleagues [29] |
2002 |
100 |
26% CMF, 11% FEC, 54% CMF + epirubicin, 9% HCST |
3 |
2 |
100 |
Retrospective, single-arm |
Ovarian function preservation |
|
| Urruticoechea and colleagues [30] |
2007 |
50 |
78% FEC, 14% AC, 8% AC-T/D |
16 |
16 |
86 |
90 |
Prospective, single-arm |
Ovarian function preservation |
|
|
|||||||||
| Total |
203 |
||||||||
|
AC, adriamycin (doxorubicin), and cyclophosphamide; AC-T, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel); AC-T/D, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel)/docetaxel; AT-CMF, adriamycin (doxorubicin), taxol (paclitaxel), cyclophosphamide, methotrexate, and 5-fluorouracil; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; HCST, high dose chemotherapy and autologous peripheral blood progenitor cell transplantation. | |||||||||
Maltaris et al. Breast Cancer Research 2008 10:206 doi:10.1186/bcr1991 |
|||||||||